We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
Medpace (MEDP - Free Report) closed the latest trading day at $405.68, indicating a +1.12% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.26%. Elsewhere, the Dow gained 0.18%, while the tech-heavy Nasdaq added 0.35%.
The the stock of provider of outsourced clinical development services has risen by 2.82% in the past month, lagging the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%.
Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. In that report, analysts expect Medpace to post earnings of $2.52 per share. This would mark year-over-year growth of 30.57%. Our most recent consensus estimate is calling for quarterly revenue of $529.73 million, up 14.94% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.29 per share and a revenue of $2.17 billion, signifying shifts of +27.14% and +14.92%, respectively, from the last year.
Any recent changes to analyst estimates for Medpace should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.53% upward. Medpace is holding a Zacks Rank of #1 (Strong Buy) right now.
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 35.55. This expresses a premium compared to the average Forward P/E of 19.51 of its industry.
Investors should also note that MEDP has a PEG ratio of 1.98 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.6.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 91, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Medpace (MEDP - Free Report) closed the latest trading day at $405.68, indicating a +1.12% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.26%. Elsewhere, the Dow gained 0.18%, while the tech-heavy Nasdaq added 0.35%.
The the stock of provider of outsourced clinical development services has risen by 2.82% in the past month, lagging the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%.
Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. In that report, analysts expect Medpace to post earnings of $2.52 per share. This would mark year-over-year growth of 30.57%. Our most recent consensus estimate is calling for quarterly revenue of $529.73 million, up 14.94% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.29 per share and a revenue of $2.17 billion, signifying shifts of +27.14% and +14.92%, respectively, from the last year.
Any recent changes to analyst estimates for Medpace should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.53% upward. Medpace is holding a Zacks Rank of #1 (Strong Buy) right now.
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 35.55. This expresses a premium compared to the average Forward P/E of 19.51 of its industry.
Investors should also note that MEDP has a PEG ratio of 1.98 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.6.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 91, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.